You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFramycetin
Accession NumberDB00452  (APRD00618)
TypeSmall Molecule
GroupsApproved
DescriptionA component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)
Structure
Thumb
Synonyms
Fradiomycin B
Framicetina
Framycetin
Framycétine
Framycetinum
Neomycin B
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sofra Tulle 10 X 10cmDressing1 %TopicalRoussel Canada Inc.1966-12-311996-09-09Canada
Sofra Tulle Strip (10 X 30cm)Dressing1 %TopicalRoussel Canada Inc.1974-12-311997-08-05Canada
Sofra-tulle Dressing 1%Dressing1 %TopicalErfa Canada 2012 Inc1994-12-31Not applicableCanada
Sofra-tulle Strip 1%Dressing1 %TopicalErfa Canada 2012 Inc1995-12-31Not applicableCanada
Soframycin Eye Drops 0.5%Solution / drops5 mgOphthalmicErfa Canada 2012 Inc2001-08-03Not applicableCanada
Soframycin Eye Drops 0.5%Solution / drops5 mgOphthalmicHoechst Roussel Canada Inc.1995-12-312000-07-28Canada
Soframycin Eye Drops 5mg/mlSolution / drops5 mgOphthalmicRoussel Canada Inc.1966-12-311997-08-05Canada
Soframycin Eye Ont 0.5%Ointment5 mgOphthalmicRoussel Canada Inc.1966-12-311997-08-05Canada
Soframycin Sterile Eye Ointment 0.5%Ointment5 mgOphthalmicHoechst Roussel Canada Inc.1995-12-312000-07-28Canada
Soframycin Sterile Eye Ointment 0.5%Ointment5 mgOphthalmicErfa Canada 2012 Inc2001-08-03Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
IsofraBouchara
IzofraBouchara
Leukase NDermapharm
PolaRoyal
Sofra-Tullesanofi-aventis
Soframycinsanofi-aventis
SoframycineMelisana
Brand mixtures
NameLabellerIngredients
Proctol OintmentOdan Laboratories Ltd
Proctol SuppositoriesOdan Laboratories Ltd
Proctosedyl OintmentAptalis Pharma Canada Inc
Proctosedyl SupRoussel Canada Inc.
Proctosedyl SuppositoriesAptalis Pharma Canada Inc
Ratio-proctosoneTeva Canada Limited
Sandoz OpticortSandoz Canada Incorporated
Sandoz Proctomyxin HCSandoz Canada Incorporated
Sandoz Proctomyxin HC SuppositoriesSandoz Canada Incorporated
Sofracort Ear/eye OintmentRoussel Canada Inc.
Sofracort Sterile Ear/eye DropsSanofi Aventis Canada Inc
Sofracort Sterile Ear/eye OintmentHoechst Roussel Canada Inc.
Soframycin Nasal SprayErfa Canada 2012 Inc
Soframycin OintmentRoussel Canada Inc.
Soframycin Skin OintmentErfa Canada 2012 Inc
Salts
Name/CASStructureProperties
Framycetin sulfate
4146-30-9
Thumb
  • InChI Key: KWBUARAINLGYMG-JGMIRXPNSA-N
  • Monoisotopic Mass: 908.21442472
  • Average Mass: 908.87
DBSALT000995
Categories
UNII4BOC774388
CAS number119-04-0
WeightAverage: 614.6437
Monoisotopic: 614.312285588
Chemical FormulaC23H46N6O13
InChI KeyPGBHMTALBVVCIT-VCIWKGPPSA-N
InChI
InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol
SMILES
NC[C@@H]1O[[email protected]](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[[email protected]](N)C[[email protected]](N)[[email protected]]3O[[email protected]]3O[[email protected]](CN)[C@@H](O)[[email protected]](O)[[email protected]]3N)[C@@H]2O)[[email protected]](N)[C@@H](O)[C@@H]1O
Pharmacology
IndicationFor the treatment of bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis. For the prophylaxis of ocular infections following foreign body removal
Structured Indications
PharmacodynamicsFramycetin is used for the treatment of bacterial eye infections such as conjunctivitis. Framycetin is an antibiotic. It is not active against fungi, viruses and most kinds of anaerobic bacteria. Framycetin works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Framycetin is useful primarily in infections involving aerobic bacteria bacteria.
Mechanism of actionFramycetin binds to specific 30S-subunit proteins and 16S rRNA, four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
TargetKindPharmacological actionActionsOrganismUniProt ID
16S rRNANucleotideyes
inhibitor
Enteric bacteria and other eubacterianot applicabledetails
30S ribosomal protein S12Proteinyes
inhibitor
Escherichia coli (strain K12)P0A7S3 details
C-X-C chemokine receptor type 4Proteinunknown
antagonist
HumanP61073 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategorySMPDB ID
Neomycin Action PathwayDrug actionSMP00256
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
AcetovanilloneAcetovanillone may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Framycetin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Alendronic acidFramycetin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Framycetin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Framycetin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Framycetin.Approved, Investigational
AmpicillinThe serum concentration of Framycetin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AnisodamineAnisodamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Framycetin.Investigational
ApremilastApremilast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Atracurium besylateFramycetin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Framycetin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Framycetin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Framycetin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Framycetin.Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Framycetin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Framycetin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicillin PotassiumThe serum concentration of Framycetin can be decreased when it is combined with Benzylpenicillin Potassium.Approved
Benzylpenicilloyl PolylysineThe serum concentration of Framycetin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
Botulinum Toxin Type AFramycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BFramycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Framycetin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Framycetin.Approved
CarbenicillinThe serum concentration of Framycetin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinFramycetin may increase the ototoxic activities of Carboplatin.Approved
CarindacillinThe serum concentration of Framycetin can be decreased when it is combined with Carindacillin.Approved
CarprofenCarprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
Cisatracurium besylateFramycetin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Framycetin.Approved
ClodronateFramycetin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Framycetin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateFramycetin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Framycetin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineFramycetin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
DecamethoniumFramycetin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Framycetin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Framycetin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Framycetin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Framycetin.Approved
Domoic AcidFramycetin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideFramycetin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
E6201E6201 may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Framycetin.Approved
EtanerceptEtanercept may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Etidronic acidFramycetin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
FenbufenFenbufen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Framycetin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Framycetin which could result in a higher serum level.Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Framycetin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Framycetin.Approved, Vet Approved
Gallamine TriethiodideFramycetin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
HMPL-004HMPL-004 may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
IbandronateFramycetin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Framycetin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
MecamylamineFramycetin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Framycetin can be decreased when it is combined with Meticillin.Approved
MetocurineFramycetin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideFramycetin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Framycetin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumFramycetin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
NafcillinThe serum concentration of Framycetin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
NeosaxitoxinFramycetin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
OlopatadineOlopatadine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Framycetin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Framycetin.Approved
OxacillinThe serum concentration of Framycetin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
PamidronateFramycetin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumFramycetin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Framycetin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Framycetin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
PipecuroniumFramycetin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Framycetin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Framycetin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Framycetin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Framycetin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Framycetin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
PyrantelFramycetin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumFramycetin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental, Investigational
RisedronateFramycetin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumFramycetin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
SRT501SRT501 may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
SuccinylcholineFramycetin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Framycetin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Framycetin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Framycetin can be decreased when it is combined with Tazobactam.Approved
Technetium tc 99m etidronateFramycetin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateFramycetin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
TenofovirThe serum concentration of Framycetin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Framycetin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Framycetin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
TiludronateFramycetin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Framycetin.Approved
TranilastTranilast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TubocurarineFramycetin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Framycetin.Approved
VecuroniumFramycetin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidFramycetin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Vanangamudi Subramaniam Sulur, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Haridas Sankar, Kuppusamy Senthilkumar, “Medicinal Cream Made Using Framycetin Sulphate and Chitosan and a Process to Make the Same.” U.S. Patent US20120101056, issued April 26, 2012.

US20120101056
General ReferencesNot Available
External Links
ATC CodesD09AA01R01AX08S01AA07
AHFS Codes
  • 52:04.04
  • 84:04.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
OintmentRectal
SuppositoryRectal
SolutionAuricular (otic); Ophthalmic
DressingTopical1 %
OintmentAuricular (otic); Ophthalmic
Solution / dropsAuricular (otic); Ophthalmic
Solution / dropsTopical
Solution / dropsOphthalmic5 mg
SprayNasal
OintmentTopical
OintmentOphthalmic5 mg
Prices
Unit descriptionCostUnit
Neomycin Sulfate 500 mg tablet1.39USD tablet
Neomycin 500 mg tablet1.25USD tablet
Neomycin sulfate powder0.84USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-7.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility64.7 mg/mLALOGPS
logP-2.8ALOGPS
logP-8.4ChemAxon
logS-0.98ALOGPS
pKa (Strongest Acidic)12.29ChemAxon
pKa (Strongest Basic)9.97ChemAxon
Physiological Charge6ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area353.11 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity135.9 m3·mol-1ChemAxon
Polarizability60.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amino sugars. These are sugars having one alcoholic hydroxy group replaced by an amino group; systematically known as x-amino-x-deoxymonosaccharides. These compounds do not include Glycosylamines.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAmino sugars
Alternative Parents
Substituents
  • 4,5-disubstituted 2-deoxystreptamine
  • Aminoglycoside core
  • 2-deoxystreptamine aminoglycoside
  • Neamine core
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Disaccharide
  • Cyclohexylamine
  • Cyclohexanol
  • Oxane
  • Oxolane
  • Cyclic alcohol
  • Secondary alcohol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

1. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
yes
Actions
inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chao PW, Chow CS: Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching. Bioorg Med Chem. 2007 Jun 1;15(11):3825-31. Epub 2007 Mar 13. [PubMed:17399988 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Trna binding
Specific Function:
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side and probably holding the rRNA structure together. The combined cluste...
Gene Name:
rpsL
Uniprot ID:
P0A7S3
Molecular Weight:
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Famulok M, Huttenhofer A: In vitro selection analysis of neomycin binding RNAs with a mutagenized pool of variants of the 16S rRNA decoding region. Biochemistry. 1996 Apr 9;35(14):4265-70. [PubMed:8605174 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vasculari...
Gene Name:
CXCR4
Uniprot ID:
P61073
Molecular Weight:
39745.055 Da
References
  1. Litovchick A, Lapidot A, Eisenstein M, Kalinkovich A, Borkow G: Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry. 2001 Dec 25;40(51):15612-23. [PubMed:11747436 ]
  2. Borkow G, Vijayabaskar V, Lara HH, Kalinkovich A, Lapidot A: Structure-activity relationship of neomycin, paromomycin, and neamine-arginine conjugates, targeting HIV-1 gp120-CXCR4 binding step. Antiviral Res. 2003 Nov;60(3):181-92. [PubMed:14638394 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46